Ovarian Cancer Screenings Raise Risk Of Health Problems And Do Not Reduce Mortality

Transvaginal ultrasound and the CA-125 blood test do not prevent females from dying of ovarian cancer - in fact the invasive medical procedures may be linked to health problems, researchers from the University of Alabama at Birmingham wrote in the Journal of the American Medical Association…

Destigmatization Needed to Cut HIV Infection Rates to Zero

To eliminate HIV, there needs to be an end to laws and policies that punish drug users and HIV-positive individuals and that criminalize behavior between consenting same-sex couples. Medscape Medical News

New War on Harmful Chemical Exposure to Enlist Physicians

Physicians need more training in environmental medicine as well as economic incentives to apply what they learn, says a coalition with a plan to protect the public from harmful chemicals. Medscape Medical News

French Regulators Suspend Pioglitazone Citing Cancer Risk

The decision to yank the drug was made after a study requested by the drug regulatory authority, AFSSAPS, confirmed a small increase in bladder cancer among patients treated with the diabetes drug. Heartwire

Sprouts to Blame for E. Coli Outbreak

(MedPage Today) — Despite no positive findings of Escherichia coli on sampled produce, German officials have determined that bean sprouts are the source of the deadliest outbreak in recent European history.

Working While Sick Common and Risky

(MedPage Today) — People who insist on working while they are sick — including those in healthcare professions — are risking their future health and productivity, warned an editorial published online in BMJ.

Cancer Risk Forces Actos Off French, German Markets

(MedPage Today) — Drug regulators in Germany and France have ordered doctors to stop prescribing the type 2 diabetes drug pioglitazone (Actos), following a French study suggesting a heightened risk of bladder cancer.

Vertex VX-770 Phase 3 STRIVE study for cystic fibrosis demonstrates improvements in lung function

Vertex Pharmaceuticals Incorporated today announced the final results from its pivotal Phase 3 STRIVE study that evaluated VX-770, a medicine in development that targets the defective protein that causes cystic fibrosis (CF).

Blinatumomab phase 2 trial results on acute lymphoblastic leukemia to be presented at EHA 2011

Data to be presented tomorrow at the 16th Annual Meeting of the European Hematology Association (EHA) in London, UK, show that Micromet’s blinatumomab produced a high complete remission rate in adult patients with acute lymphoblastic leukemia (ALL) who had relapsed following treatment with standard therapy.

FDA accepts ZIOPHARM’s IND for ZIN ATI-001 to treat melanoma

ZIOPHARM Oncology, Inc., a drug development company employing small molecule and synthetic biology approaches to cancer therapy, announced today that the U.S. Food & Drug Administration has accepted the Company’s investigational new drug application to begin clinical study of ZIN ATI-001, a novel DNA-based therapeutic candidate also known as Ad-RTS-IL-12 + AL, in oncology.